The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy
Effect of the Radioiodine Dose in Thyroid Ablation- A Randomized Comparison of 1110 MBq to 3700 MBq
Sponsor: Helsinki University Central Hospital
Listed as NCT00115895, this PHASE3 trial focuses on Thyroid Neoplasms and remains ongoing. Sponsored by Helsinki University Central Hospital, it has been updated 7 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Apr 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Jan 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Helsinki University Central Hospital
- University of Helsinki
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Helsinki, Finland